Apps

openserveblockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

News

Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

IJR News — today's news from every side

Jaguar Health Reports Q2 2026 Financials — Aug 18, 2026Jaguar Health reported Q2 2026 results showing revenue of about $1.23 million and a net loss of $12.68 million, with six-month revenue of $21.5 million and a net loss of $3.83 million, while highlighting crofelemer data that reduced parenteral support by up to 48% in microvillus inclusion disease and outlining a NDA package targeted for end of 2026 and an NDA submission in Q2 2027. The company also announced an investor webcast for August 19, 2026 to review the quarter and corporate updates, and reiterated its focus on crofelemer for rare gastrointestinal disorders and related partnerships.